Immunomic Therapeutics to Present at China Focus @BIO Philadelphia

ROCKVILLE, Md.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/allergies?src=hash" target="_blank"gt;#allergieslt;/agt;–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based
biotechnology company, announced today that the company will present at
the China Focus @BIO being held in Philadelphia, Pennsylvania, June 2,
2019. Yan Su, Ph.D., Immunomic’s advisor for China and Corporate
Development, will present a company overview and will discuss ITI’s
recently expanded, investigational UNiversal Intracellular Targeted
Expression (UNITE) platform and its application in immuno-oncology,
specifically glioblastoma multiforme (GBM). ITI’s technology platform
has the potential to utilize the body’s natural biochemistry to develop
a broad immune response and is currently being employed in a Phase II
clinical trial as a cancer immunotherapy.

Presentation details are as follows:

Title: Investigational Cell and Nucleic Based Vaccine
Immunotherapies for China and SEA
Panel Date and Time: Sunday,
June 2, 2019 2:10 PM
Location: Commonwealth Hall CD (Track 1)
Place:
Loews Philadelphia Hotel, Philadelphia, PA

About UNITE

ITI’s investigational UNITE platform, or UNiversal Intracellular
Targeted Expression, is thought to work by encoding the Lysosomal
Associated Membrane Protein, an endogenous protein in humans. In this
way, ITI’s vaccines (DNA or RNA) have the potential to utilize the
body’s natural biochemistry to develop a broad immune response including
antibody production, cytokine release and critical immunological memory.
This approach could put UNITE technology at the crossroads of
immunotherapies in a number of illnesses, including cancer, allergy and
infectious diseases. UNITE is currently being employed in Phase II
clinical trials as a cancer immunotherapy. ITI is also collaborating
with academic centers and biotechnology companies to study the use of
UNITE in cancer types of high mortality, including cases where there are
limited treatment options like glioblastoma and acute myeloid leukemia.
ITI believes that these early clinical studies may provide a proof of
concept for UNITE therapy in cancer, and if successful, set the stage
for future studies, including combinations in these tumor types and
others. Preclinical data is currently being developed to explore whether
LAMP nucleic acid constructs may amplify and activate the immune
response in highly immunogenic tumor types and be used to create immune
responses to tumor types that otherwise do not provoke an immune
response.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage
biotechnology company pioneering the development of vaccines through its
proprietary technology platform, UNiversal Intracellular Targeted
Expression (UNITE), which is designed to utilize the body’s natural
biochemistry to develop vaccines that generate broad immune responses.
ITI’s UNITE platform could potentially have broad therapeutic
applications in oncology, including viral antigens, cancer antigens,
neoantigens and antigen-derived antibodies as biologics and ITI has
built a large pipeline from UNITE with six oncology programs and two
allergy programs. ITI has entered into a significant allergy partnership
with Astellas Pharma and has formed several academic collaborations with
leading Immuno-oncology researchers at Fred Hutchinson Cancer Research
Institute, Johns Hopkins University of Medicine, Duke University. ITI
maintains its headquarters in Rockville, Maryland. For more information,
please visit www.immunomix.com.

Contacts

Company Contact:
Sia Anagnostou
[email protected]
717-327-1822

Media Contact:
Amy Conrad
Juniper Point
[email protected]
858-366-3243